Orthostatic hypotension

Global Orthostatic Hypotension Drugs Markets to 2023 with Sales Data on Midodrine, Northera (Droxidopa), Fludrocortisone, and Other Drugs

Retrieved on: 
Monday, August 19, 2019
Drugs, Organic compounds, Chemistry, Hypotension, Vascular diseases, Prodrugs, Acetamides, Midodrine, Phenethylamines, Orthostatic hypotension, Standing, Fludrocortisone

Dublin, Aug. 19, 2019 (GLOBE NEWSWIRE) -- The "Orthostatic Hypotension Drugs Market by Product and Geography - Global Forecast and Analysis 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Dublin, Aug. 19, 2019 (GLOBE NEWSWIRE) -- The "Orthostatic Hypotension Drugs Market by Product and Geography - Global Forecast and Analysis 2019-2023" report has been added to ResearchAndMarkets.com's offering.
  • The orthostatic hypotension drugs market analysis considers sale from midodrine, northera (droxidopa), fludrocortisone, and other drugs.
  • Our analysis also considers the orthostatic hypotension drugs market in Asia, Europe, North America, and RoW.
  • With the presence of several major players, global orthostatic hypotension drugs market is moderately fragmented.

Global Orthostatic Hypotension Drugs Market by Product & Geography (2019-2023) - ResearchAndMarkets.com

Retrieved on: 
Monday, August 19, 2019
Health, Pharmaceutical, Drugs, Organic compounds, Chemistry, Vascular diseases, Prodrugs, Acetamides, Midodrine, Phenethylamines, Orthostatic hypotension, Standing, Hypotension, Fludrocortisone

The "Orthostatic Hypotension Drugs Market by Product and Geography - Global Forecast and Analysis 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Orthostatic Hypotension Drugs Market by Product and Geography - Global Forecast and Analysis 2019-2023" report has been added to ResearchAndMarkets.com's offering.
  • The orthostatic hypotension drugs market analysis considers sale from midodrine, northera (droxidopa), fludrocortisone, and other drugs.
  • Our analysis also considers the orthostatic hypotension drugs market in Asia, Europe, North America, and RoW.
  • With the presence of several major players, global orthostatic hypotension drugs market is moderately fragmented.

Global Orthostatic Hypotension Drugs Market 2019-2023 | Use of Combination Therapy in OH Treatment to Boost Growth | Technavio

Retrieved on: 
Friday, August 9, 2019
Health, Pharmaceutical, Drugs, Vascular diseases, Organic compounds, Organ systems, Prodrugs, Orthostatic hypotension, RTT, Midodrine, Hypotension, Fludrocortisone

View the full release here: https://www.businesswire.com/news/home/20190809005147/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190809005147/en/
    Technavio has published a new market research report on the global orthostatic hypotension (OH) drugs market from 2019-2023.
  • This global orthostatic hypotension drugs market 2019-2023 research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.
  • Global Orthostatic Hypotension Drugs Market: Use of Combination Therapy in OH Treatment
    OH is a chronic, debilitating illness that is difficult to treat in several patients.
  • Global Orthostatic Hypotension Drugs Market: Segmentation Analysis
    This market research report segments the global orthostatic hypotension drugs market by product (midodrine, Northera (droxidopa), fludrocortisone, and other drugs) and geographical regions (North America, Europe, Asia, and ROW).

Theravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Oral Presentation at 32nd European Neurology Congress

Retrieved on: 
Monday, July 22, 2019
Hypotension, Orthostatic hypotension, Antidepressants, Amines, Serotonin-norepinephrine reuptake inhibitors

DUBLIN, July 22, 2019 /PRNewswire/ --Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today reported new data from the Company's Phase 2 clinical trial of ampreloxetine (TD-9855) in patients with neurogenic orthostatic hypotension (nOH) in an oral presentation at the 32nd European Neurology Congress.

Key Points: 
  • DUBLIN, July 22, 2019 /PRNewswire/ --Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today reported new data from the Company's Phase 2 clinical trial of ampreloxetine (TD-9855) in patients with neurogenic orthostatic hypotension (nOH) in an oral presentation at the 32nd European Neurology Congress.
  • The 32nd European Neurology Congress (ENC) is being held July 22-24, 2019 in London.
  • Ampreloxetine is an investigational, once-daily oral norepinephrine reuptake inhibitor (NRI) in development for the treatment of patients with symptomatic nOH.
  • The ENC presentation reported data from the Company's completed Phase 2 clinical study, which evaluated the efficacy, durability and safety of once-daily oral ampreloxetine in patients with nOH.

The Food and Drug Administration (FDA) Determines that Women Taking Addyi May Safely Consume Alcohol

Retrieved on: 
Friday, April 12, 2019
Human sexuality, Hypotension, Vascular diseases, Chemical compounds, Organic compounds, RTT, Dopamine agonists, Piperazines, Flibanserin, Hypoactive sexual desire disorder, Orthostatic hypotension, Syncope

This decision was informed by three new Addyi alcohol interaction studies which demonstrated no syncope or orthostatic hypotension requiring medical attention.

Key Points: 
  • This decision was informed by three new Addyi alcohol interaction studies which demonstrated no syncope or orthostatic hypotension requiring medical attention.
  • Sprout received the FDA ordered Addyi labeling change to lessen the alcohol restriction on April 11, 2019.
  • "FDA, like us, recognizes that women want access to treatment for this condition and their label order reflecting that women taking Addyi may safely consume alcohol is a positive step.
  • Addyi is the first and only FDA-approved treatment for acquired, generalized hypoactive (low) sexual desire disorder (HSDD) for premenopausal women.

How Low is Too Low? Study Highlights Serious Risks for Intensive Blood Pressure Control

Retrieved on: 
Thursday, August 23, 2018
Vascular diseases, Hypotension, Medicine, Anatomy, Orthostatic hypotension, Blood pressure, Nervous system, Syncope, Standing, Blood, Baroreceptor, Spontaneous cerebrospinal fluid leak

"But our study shows that attaining a lower blood pressure could create to a subpopulation of patients whose blood pressures may go too low, which can pose risk for serious falls and fainting."

Key Points: 
  • "But our study shows that attaining a lower blood pressure could create to a subpopulation of patients whose blood pressures may go too low, which can pose risk for serious falls and fainting."
  • He noted that older patients are more likely to have acute reductions in blood pressure, such as orthostatic hypotension, which is when a patient's blood pressure drops substantially when they stand or get upright, and have slower reflexes to compensate and normalize their blood pressure.
  • They also are more susceptible to side effects of low blood pressure, he said.
  • Some characteristics physicians should watch out for before considering lowering a patient's blood pressure are acute illness, blood pressure variation throughout the day, and orthostatic hypotension, Dr. Sim said.

Theravance Biopharma to Host Key Opinion Leader Event Focused on the Unmet Medical Need in the Treatment of Neurogenic Orthostatic Hypotension

Retrieved on: 
Thursday, May 17, 2018
Hypotension, Orthostatic hypotension, Serotonin reuptake inhibitor, Anatomy

DUBLIN, May 17, 2018 /PRNewswire/ --Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a key opinion leader event focusing on neurogenic orthostatic hypotension (nOH) beginning at 12:00 p.m.

Key Points: 
  • DUBLIN, May 17, 2018 /PRNewswire/ --Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a key opinion leader event focusing on neurogenic orthostatic hypotension (nOH) beginning at 12:00 p.m.
  • The event will feature a presentation by key opinion leader Roy Freeman, MB ChB, Harvard Medical School and the Beth Israel Deaconess Medical Center, who will discuss the current treatment landscape and unmet medical need in nOH.
  • Theravance Biopharma is developing TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor (NSRI), for the treatment of patients with symptomatic nOH.
  • THERAVANCE, the Cross/Star logo, and VIBATIV are registered trademarks of the Theravance Biopharma group of companies.